RxDoctor Payments Data

Chao-Huang Sun

Nephrology · Riverside, CANPI 1134174493

Payments from drug & device makers

What this record shows

Astrazeneca UK Limited accounts for 74.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $1,216 and has fallen 86.3% since, to $167 in 2022.

$1,612in general payments, 2019–2025

Across 23 payments — averaging $70.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$1K
  • Travere Therapeutics, Inc.$149
  • AstraZeneca$90
  • Amgen$82
  • Akebia Therapeutics Inc$39
  • Vifor Pharma, Inc.$25
  • plus $28 from 2 others
$453,577in research payments, 2019–2025

Across 222 payments — averaging $2043.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$204K
  • GSK$147K
  • Astrazeneca AB$65K
  • Baxter Healthcare$15K
  • Gilead$8K
  • Boehringer Ingelheim$6K
  • plus $10K from 5 others

What the payments were for

  • Travel & lodging$88855%
  • Food & beverage$72445%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,612 in reported general payments places this provider in the 55th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Other nephrology in Riverside

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →